Exhibit 99.1
Chembio Diagnostics Reports First Quarter 2022 Financial Results
HAUPPAUGE, NY, May 5, 2022 -- Chembio Diagnostics, Inc. (“Chembio” or the “Company”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious
diseases, today reported financial results for the quarter ended March 31, 2022.
Recent Highlights
|
• |
Achieved total revenue of $18.8 million including record quarterly product revenue of $18.5 million in the first quarter of 2022, representing growth of 116% and 360%, respectively, compared to the prior year period:
|
|
o |
U.S. product revenue of $4.5 million, representing growth of 530% compared to the prior year period
|
|
o |
Latin America product revenue of $12.5 million, compared to $0.3 million in the prior year period
|
|
• |
Completed shipments under the $28.3 million purchase order from Bio-Manguinhos for DPP SARS-COV-2 Antigen Tests in Brazil and continued shipments on the $4 million HIV test purchase order supported by The Global Fund, which are expected
to be completed in the second quarter of 2022
|
|
• |
Improved gross product margin to 18% in the first quarter of 2022 from negative 9% in the fourth quarter of 2021
|
|
• |
Reduced cash usage in the first quarter of 2022 to $4.4 million, from $8.7 million in the prior year period and $7.2 million in the preceding quarter
|
|
• |
Expanded distributor relationships in Europe to supply the Sure Check HIV Self-tests in the UK and France
|
|
• |
Enhanced operations at Chembio Diagnostics Brazil by increasing low-cost manufacturing capabilities for over-the-counter packaging to support Sure Check Self-test supply for state, local and retail pharmacies
|
“We are pleased with our first quarter performance which included record quarterly product sales and substantial sequential gross product margin improvement,” said
Richard Eberly, Chembio’s President and Chief Executive Officer. “In light of decreasing international demand for COVID-19 testing, we are repositioning our commercial focus toward our core products. The HIV self-testing market continues to grow
across Europe, Brazil and Africa, and with renewed marketing efforts we believe our Sure Check products can address the needs of this patient population and further penetrate this market. Going forward, we will continue to prioritize use of our
resources to drive more profitable growth and operational efficiency in accordance with our previously announced Global Competitiveness Program.”
First Quarter 2022 Financial Results
Total revenue for the first quarter of 2022 was $18.8 million, an increase of 116% compared to the prior year period. Net product sales for the first quarter of 2022
were $18.5 million, an increase of 360% compared to the prior year period. Government grant, license and royalty, and R&D revenue for the first quarter of 2022 totaled $0.3 million, a decrease of 94% compared to the prior year period.
Gross product margin for the first quarter of 2022 was $3.3 million, compared to $0.5 million for the prior year period. Gross product margin percentage for the first
quarter of 2022 was 18%, compared to 12% for the prior year period. Gross product margin in the first quarter of 2022 was driven by increased product volume sold in US and Latin America at higher average selling prices and operational productivity.
Research and development expenses decreased by $1.2 million, or 42%, in the first quarter of 2022 compared to the prior year period. Selling, general and
administrative expenses increased by $0.9 million, or 14%, in the first quarter of 2022 compared to the prior year period.
Impairment, restructuring, severance and related costs for the first quarter of 2022 totaled $3.0 million, including an impairment of goodwill.
Net loss for the first quarter of 2022 was $8.8 million, or $0.29 per diluted share, compared to a net loss of $4.5 million, or $0.22 per diluted share, for the
prior year period. The net loss includes impairment, restructuring, severance and related costs of $3.0 million, or $0.10 per share, for the first quarter of
2022, compared to a de minimis amount in the prior year period.
Cash and cash equivalents as of March 31, 2022 totaled $24.4 million, compared to $28.8 million at December 31, 2021.
Going Concern Considerations
The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems
during the continuing, but evolving, uncertainty caused by COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters.
The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the
Company’s ability to continue as a going concern within one year after the date the Company’s unaudited condensed consolidated financial statements for the three months ended March 31, 2022 are being issued (the “Q1 Financials Issuance Date”).
Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment,
management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the Q1 Financials Issuance Date and (2) when implemented, would mitigate the
relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern.
The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps, including investments in
automation, to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months
ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:
| • |
Focus on higher margin business in growth markets
|
| • |
Lower manufacturing costs
|
| • |
Reduce infrastructure costs
|
| • |
Strategic review of non-core businesses and assets:
|
In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis
test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the Q1 Financials Issuance Date. The Company’s
execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all.
The Company considered in particular how:
| • |
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by,
for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.
|
| • |
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the
suppliers of those products.
|
The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in its existing Credit
Agreement. Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements
range from $43.8 million for the twelve months ending June 30, 2022 to$ 48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding
thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement
or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern.
The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a
material adverse effect on its business, prospects, results of operations, liquidity and financial condition.
Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the
Q1 Financials Issuance Date. Without giving effect to the prospect of raising additional capital pursuant to the Company’s existing At the Market Offering Agreement, increasing product revenue in the near future or executing other mitigating plans,
many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The
existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the Q1 Financials Issuance Date.
The Company’s unaudited condensed consolidated financial statements for the three months ended March 31, 2022 have been prepared assuming the Company will continue as
a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the Q1 Financials Issuance Date. As such, those unaudited
condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be
unable to continue as a going concern.
Conference Call
Chembio will host a conference call today beginning at 4:30 pm ET to discuss its financial results and recent business highlights. Investors interested in listening to
the call may do so by dialing 888-506-0062 from the United States or 973-528-0011 from outside the United States and providing entry code 898553. To listen to a live webcast of the call, please visit the Investor Relations section of Chembio's
website at www.chembio.com. Following the call, a replay will be available on the Investor Relations section of Chembio’s website. A telephone replay will be available until 4:30 pm ET on May 19, 2022 by dialing 877-481-4010 from the United States
or 919-882-2331 from outside the United States and using passcode 45278.
About Chembio Diagnostics
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used for the rapid detection and diagnosis of infectious
diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment. Coupled with Chembio’s extensive scientific expertise, its novel DPP technology
offers broad market applications beyond infectious disease. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government
agencies, and consumers. Learn more at www.chembio.com.
Forward-Looking Statements
Certain statements contained in the second bulleted item
under “Recent Highlights” above and in the paragraph following the bulleted items under “Recent Highlights” above are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements include statements regarding the intent, belief or current expectations with respect to the Chembio’s R&D investments, development of certain products and registration of existing products in new
geographies. Such statements, which are expectations only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events or performance may differ materially from
forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the following, any of which could be exacerbated even further by the continuing COVID-19 outbreak
in the United States and globally: the ability of Chembio to continue to generate revenue from the HIV test purchase order supported by The
Global Fund or other product orders, and the margins it can realize from that revenue, or its ability to develop new products, will depend on the availability and cost of human, material and other resources required to build and deliver the
tests, which factors are largely outside Chembio’s control; the ability of Chembio to maintain existing, and timely obtain additional, regulatory approvals, which approvals are subject to processes that can change recurringly without notice;
the highly competitive and rapidly developing diagnostics market, which includes a number of competing companies with strong relationships with current and potential customers, including governmental authorities, and with significantly greater
financial and other resources that are available to Chembio; and the risks of doing business with foreign governmental entities, including geopolitical, international and other challenges as well as potential material adverse effects of tariffs
and other changes in U.S. trade policy. Chembio undertakes no obligation to publicly update forward-looking statements in this release to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's
expectations with regard to the forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's periodic public filings with the U.S. Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021, particularly under the heading “Risk Factors.”
DPP is Chembio’s registered trademark, and the Chembio logo is
Chembio’s trademark. For convenience, these trademarks appear in this release without ® or ™ symbols, but that practice does not mean that Chembio will not assert, to the fullest extent under applicable law, its rights to the
trademarks. All other trademarks appearing in this release are the property of their
respective owners.
Investor Relations Contact
Philip Taylor
Gilmartin Group
(415) 937-5406
investor@chembio.com
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| |
|
For the three months ended
(Unaudited)
|
|
| |
|
March 31, 2022
|
|
|
March 31, 2021
|
|
|
REVENUES:
|
|
|
|
|
|
|
|
Product revenue
|
|
$
|
18,527,456
|
|
|
$
|
4,024,662
|
|
|
R&D revenue
|
|
|
18,173
|
|
|
|
1,106,639
|
|
|
Government grant income
|
|
|
-
|
|
|
|
3,350,000
|
|
|
License and royalty revenue
|
|
|
270,982
|
|
|
|
243,058
|
|
|
TOTAL REVENUES
|
|
|
18,816,611
|
|
|
|
8,724,359
|
|
| |
|
|
|
|
|
|
|
|
|
COSTS AND EXPENSES:
|
|
|
|
|
|
|
|
|
|
Cost of product revenue
|
|
|
15,223,861
|
|
|
|
3,548,441
|
|
|
Research and development expenses
|
|
|
1,653,706
|
|
|
|
2,863,338
|
|
|
Selling, general and administrative expenses
|
|
|
6,946,271
|
|
|
|
6,085,067
|
|
|
Impairment, restructuring, severance and related costs
|
|
|
3,043,179
|
|
|
|
83,087
|
|
|
TOTAL COSTS AND EXPENSES
|
|
|
26,867,017
|
|
|
|
12,579,933
|
|
|
LOSS FROM OPERATIONS
|
|
|
(8,050,406
|
)
|
|
|
(3,855,574
|
)
|
| |
|
|
|
|
|
|
|
|
|
OTHER EXPENSE:
|
|
|
|
|
|
|
|
|
|
Interest expense, net
|
|
|
(733,561
|
)
|
|
|
(712,477
|
)
|
| |
|
|
|
|
|
|
|
|
|
LOSS BEFORE INCOME TAXES
|
|
|
(8,783,967
|
)
|
|
|
(4,568,051
|
)
|
| |
|
|
|
|
|
|
|
|
|
Income tax (expense)/benefit
|
|
|
(6,327
|
)
|
|
|
67,888
|
|
| |
|
|
|
|
|
|
|
|
|
NET LOSS
|
|
$
|
(8,790,294
|
)
|
|
$
|
(4,500,163
|
)
|
| |
|
|
|
|
|
|
|
|
|
Basic and diluted loss per share
|
|
$
|
(0.29
|
)
|
|
$
|
(0.22
|
)
|
| |
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding, basic and diluted
|
|
|
30,090,045
|
|
|
|
20,163,386
|
|
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF
| |
|
March 31, 2022
|
|
|
December 31, 2021
|
|
| |
|
|
|
|
|
|
|
- ASSETS -
|
|
|
|
|
|
|
|
CURRENT ASSETS:
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
24,399,388
|
|
|
$
|
28,772,892
|
|
|
Accounts receivable
|
|
|
9,879,954
|
|
|
|
11,441,107
|
|
|
Inventories, net
|
|
|
11,844,121
|
|
|
|
12,920,451
|
|
|
Prepaid expenses and other current assets
|
|
|
2,097,491
|
|
|
|
2,096,399
|
|
|
TOTAL CURRENT ASSETS
|
|
|
48,220,954
|
|
|
|
55,230,849
|
|
| |
|
|
|
|
|
|
|
|
|
FIXED ASSETS:
|
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net
|
|
|
8,414,313
|
|
|
|
8,556,773
|
|
|
Finance lease right-of-use asset, net
|
|
|
190,526
|
|
|
|
191,870
|
|
|
TOTAL FIXED ASSETS, net
|
|
|
8,604,839
|
|
|
|
8,748,643
|
|
| |
|
|
|
|
|
|
|
|
|
OTHER ASSETS:
|
|
|
|
|
|
|
|
|
|
Operating lease right-of-use assets, net
|
|
|
5,693,482
|
|
|
|
5,891,906
|
|
|
Goodwill
|
|
|
-
|
|
|
|
3,022,787
|
|
|
Deposits and other assets
|
|
|
370,940
|
|
|
|
358,010
|
|
| |
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
$
|
62,890,215
|
|
|
$
|
73,252,195
|
|
| |
|
|
|
|
|
|
|
|
|
- LIABILITIES AND STOCKHOLDERS’ EQUITY -
|
|
|
|
|
|
|
|
|
|
CURRENT LIABILITIES:
|
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities
|
|
$
|
10,542,851
|
|
|
$
|
13,127,993
|
|
|
Current portion of long-term debt
|
|
|
2,100,000
|
|
|
|
1,200,000
|
|
|
Operating lease liabilities
|
|
|
916,524
|
|
|
|
886,294
|
|
|
Finance lease liabilities
|
|
|
72,203
|
|
|
|
68,176
|
|
|
TOTAL CURRENT LIABILITIES
|
|
|
13,631,578
|
|
|
|
15,282,463
|
|
| |
|
|
|
|
|
|
|
|
|
OTHER LIABILITIES:
|
|
|
|
|
|
|
|
|
|
Long-term operating lease liabilities
|
|
|
5,733,214
|
|
|
|
5,976,151
|
|
|
Long-term finance lease liabilities
|
|
|
134,955
|
|
|
|
139,678
|
|
|
Long-term debt, less current portion, net
|
|
|
16,855,322
|
|
|
|
17,589,003
|
|
|
TOTAL LIABILITIES
|
|
|
36,355,069
|
|
|
|
38,987,295
|
|
| |
|
|
|
|
|
|
|
|
|
STOCKHOLDERS’ EQUITY:
|
|
|
|
|
|
|
|
|
|
Common stock - $0.01 par value
|
|
|
302,699
|
|
|
|
301,050
|
|
|
Additional paid-in capital
|
|
|
166,483,376
|
|
|
|
165,772,636
|
|
|
Accumulated deficit
|
|
|
(139,800,154
|
)
|
|
|
(131,009,860
|
)
|
|
Treasury stock
|
|
|
(206,554
|
)
|
|
|
(206,554
|
)
|
|
Accumulated other comprehensive (loss)
|
|
|
(244,221
|
)
|
|
|
(592,372
|
)
|
|
TOTAL STOCKHOLDERS’ EQUITY
|
|
|
26,535,146
|
|
|
|
34,264,900
|
|
| |
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
|
|
$
|
62,890,215
|
|
|
$
|
73,252,195
|
|
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
(Unaudited)
| |
|
March 31, 2022
|
|
|
March 31, 2021
|
|
| |
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
$
|
(4,368,959
|
)
|
|
$
|
(7,261,260
|
)
|
|
Net cash used in investing activities
|
|
|
(286,544
|
)
|
|
|
(1,239,168
|
)
|
|
Net cash used by financing activities
|
|
|
(55,444
|
)
|
|
|
(129,341
|
)
|
|
Effect of exchange rate changes on cash
|
|
|
337,442
|
|
|
|
(85,579
|
)
|
|
INCREASE IN CASH AND CASH EQUIVALENTS
|
|
|
(4,373,504
|
)
|
|
|
(8,715,348
|
)
|
|
Cash and cash equivalents - beginning of the period
|
|
|
28,772,892
|
|
|
|
23,066,301
|
|
|
Cash and cash equivalents - end of the period
|
|
$
|
24,399,388
|
|
|
$
|
14,350,953
|
|
